GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyadic International Inc (NAS:DYAI) » Definitions » Cash per Share

Dyadic International (Dyadic International) Cash per Share : $0.41 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Dyadic International Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Dyadic International's Cash per Share for the quarter that ended in Mar. 2024 was $0.41.


Dyadic International Cash per Share Historical Data

The historical data trend for Dyadic International's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyadic International Cash per Share Chart

Dyadic International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.25 1.06 0.72 0.44 0.25

Dyadic International Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.35 0.28 0.25 0.41

Dyadic International Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Dyadic International's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Dyadic International's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dyadic International  (NAS:DYAI) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


Dyadic International Cash per Share Related Terms

Thank you for viewing the detailed overview of Dyadic International's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Dyadic International (Dyadic International) Business Description

Traded in Other Exchanges
N/A
Address
140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL, USA, 33477
Dyadic International Inc is a global biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Executives
Ronen Tchelet officer: VP of Research and Bus. Dvlpmt 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Mark A Emalfarb director, 10 percent owner, officer: President, CEO & Chairman C/O DYADIC INTERNATIONAL, INC., 140 INTRACOASTAL POINT DRIVE, SUITE 404, JUPITER FL 33477-5094
Joseph P Hazelton officer: Chief Business Officer 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER FL 33477
Francisco Trust Under Agreement Dated February 28, 1996 10 percent owner C/O ROBERT S. LEVIN, ESQ., TRUSTEE, 180 NORTH LASALLE STREET, SUITE 3200, CHICAGO IL 60601
Patrick K. Lucy director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Matthew S. Jones officer: Managing Dir of BD & Licensing 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Seth Herbst director 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Barry Buckland director C/O DYADIC INTERNATIONAL, INC., 140 INTERCOASTAL POINTE DR SUITE 404, JUPITER FL 33477
Ping Wang Rawson officer: Chief Financial Officer 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Michael P. Tarnok director KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Arindam Bose director 4452 BELTWAY DRIVE, ADDISON TX 75001
Jack Kaye director C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Tom Juda 10 percent owner 410 S LUCERNE BLVD, LOS ANGELES CA 90020
John Steven Emerson 10 percent owner 1522 ENSLEY AVENUE, LOS ANGELES CA 90024
Nancy Juda 10 percent owner 410 S LUCERNE BLVD, LOS ANGELES CA 90020